Polyrizon Announces The Initiation Of Preclinical Studies For Intranasal Benzodiazepines, A Treatment For Acute Repetitive Seizures And Status Epilepticus, Using Its Proprietary Drug Delivery Platform

Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform.

According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects.  The global acute repetitive seizures market size was estimated at USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030.

According to the latest research study, the global epilepsy treatment devices market was valued at approximately USD 526.8 Million in 2023 and is expected to reach a value of around USD 787.3 Million by 2033, growing at a compound annual growth rate (CAGR) of about 4.1% during the forecast period 2024 to 2033.

The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board.